(19)
(11) EP 1 830 939 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.02.2011 Bulletin 2011/08

(45) Mention of the grant of the patent:
10.11.2010 Bulletin 2010/45

(21) Application number: 05770617.8

(22) Date of filing: 18.07.2005
(51) International Patent Classification (IPC): 
B01D 15/08(2006.01)
 G01N 30/60(2006.01)
(86) International application number:
PCT/EP2005/007809
(87) International publication number:
WO 2006/048058 (11.05.2006 Gazette 2006/19)

(54)

CHROMATOGRAPHY COLUMN

CHROMATOGRAPHIESÄULE

COLONNE CHROMATOGRAPHIQUE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 02.11.2004 GB 0424259

(43) Date of publication of application:
12.09.2007 Bulletin 2007/37

(73) Proprietor: GE Healthcare Bio-Sciences AB
751 84 Uppsala (SE)

(72) Inventors:
  • USELIUS, Per
    S-752 67 Uppsala (SE)
  • OLSSON, Mats GE Healthcare Bio-Sciences AB
    751 84 Uppsala (SE)
  • WOUNDER, Sven GE Healthcare Bio-Sciences AB
    S- 752 75 Uppsala (SE)
  • PERSSON, Jerker GE Healthcare Bio-Sciences AB
    S-752 75 Uppsala (SE)

(74) Representative: Stavbom, Ellen Elisabet et al
GE Healthcare Bio-Sciences AB Patent Department Björkgatan 30
751 84 Uppsala
751 84 Uppsala (SE)


(56) References cited: : 
WO-A1-03/076923
US-A1- 2002 153 321
 US-A- 5 217 608
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).